A

Atrys Health SA
MAD:ATRY

Watchlist Manager
Atrys Health SA
MAD:ATRY
Watchlist
Price: 2.89 EUR -0.34% Market Closed
Market Cap: €219.7m

Atrys Health SA
Revenue

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Atrys Health SA
Revenue Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Revenue CAGR 3Y CAGR 5Y CAGR 10Y
A
Atrys Health SA
MAD:ATRY
Revenue
€141m
CAGR 3-Years
-4%
CAGR 5-Years
35%
CAGR 10-Years
N/A
No Stocks Found

Atrys Health SA
Glance View

Market Cap
219.7m EUR
Industry
Health Care

Atrys Health SA is a biomedical company, which engages in the research and development of diagnostic services. The company is headquartered in Madrid, Madrid and currently employs 2,397 full-time employees. The company went IPO on 2016-07-22. The company operates under Atrys brand name. Atrys is a clinical and translational research laboratory dedicated to the diagnosis, prognosis and treatment of cancer, including hematologic and solid malignancies. The company has four areas of activity: Laboratory, Telemedicine, Radiotherapy, as well as Research and Development (R&D). The firm has its diagnostic laboratories and translational research in Barcelona and Granada, and offices in Madrid, Spain.

ATRY Intrinsic Value
3.77 EUR
Undervaluation 23%
Intrinsic Value
Price €2.89
A

See Also

What is Atrys Health SA's Revenue?
Revenue
141m EUR

Based on the financial report for Dec 31, 2025, Atrys Health SA's Revenue amounts to 141m EUR.

What is Atrys Health SA's Revenue growth rate?
Revenue CAGR 5Y
35%

Over the last year, the Revenue growth was -34%. The average annual Revenue growth rates for Atrys Health SA have been -4% over the past three years , 35% over the past five years .

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett